Payment overview · 2025
General Payments
$715.15
47 reported records · 8 companies
Healthcare provider profile · identity verified
Jeffrey A. Medlock, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ALMA, AR · NPI 1689692360
Verified facts
What the public records show
CMS Open Payments records show Jeffrey A. Medlock, M.D. received $715.15 in general payments during 2025 across 47 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $160.60 | 22.5% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $147.46 | 20.6% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $146.56 | 20.5% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $143.87 | 20.1% | 10 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.54 | 6.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.80 | 5.3% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.26 | 2.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.06 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $715.15 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $160.60 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $143.87 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $122.50 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $80.86 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $66.60 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $47.54 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.78 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.80 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.80 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $6.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
78 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 839 | 121 |
| Atorvastatin Calcium | Atorvastatin Calcium | 500 | 139 |
| Lisinopril | Lisinopril | 407 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 366 | 112 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 343 | 108 |
| Tamsulosin Hcl | Tamsulosin Hcl | 284 | 77 |
| Gabapentin | Gabapentin | 268 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 266 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 255 | 61 |
| Omeprazole | Omeprazole | 242 | 73 |
| Potassium Chloride | Potassium Chloride | 231 | 66 |
| Lorazepam | Lorazepam | 211 | 37 |
| Furosemide | Furosemide | 203 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 67 |
| Alendronate Sodium | Alendronate Sodium | 184 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 52 |
| Losartan Potassium | Losartan Potassium | 167 | 53 |
| Ropinirole Hcl | Ropinirole Hcl | 164 | 36 |
| Simvastatin | Simvastatin | 163 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 142 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 138 | 38 |
| Metformin Hcl | Metformin Hcl | 136 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 126 | 25 |
| Trazodone Hcl | Trazodone Hcl | 123 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 42 |
| Metformin Hcl Er | Metformin Hcl | 116 | 32 |
| Azithromycin | Azithromycin | 108 | 78 |
| Sertraline Hcl | Sertraline Hcl | 108 | 26 |
| Eliquis | Apixaban | 105 | 20 |
| Tramadol Hcl | Tramadol Hcl | 104 | 23 |
| Carvedilol | Carvedilol | 103 | 28 |
| Ezetimibe | Ezetimibe | 103 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 25 |
| Ondansetron Odt | Ondansetron | 101 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 30 |
| Montelukast Sodium | Montelukast Sodium | 97 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 97 | 22 |
| Allopurinol | Allopurinol | 94 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 21 |
| Methocarbamol | Methocarbamol | 93 | 22 |
| Alprazolam | Alprazolam | 92 | 14 |
| Clonazepam | Clonazepam | 92 | 19 |
| Famotidine | Famotidine | 91 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 91 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 23 |
| Solifenacin Succinate | Solifenacin Succinate | 85 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 82 | 12 |
| Xarelto | Rivaroxaban | 80 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 78 | 22 |
| Topiramate | Topiramate | 78 | 25 |
| Ventolin Hfa | Albuterol Sulfate | 77 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 23 |
| Meloxicam | Meloxicam | 75 | 21 |
| Mirtazapine | Mirtazapine | 75 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 72 | 17 |
| Mupirocin | Mupirocin | 72 | 45 |
| Clonidine Hcl | Clonidine Hcl | 71 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 71 | 20 |
| Pregabalin | Pregabalin | 71 | 15 |
| Cefuroxime | Cefuroxime Axetil | 70 | 53 |
| Dutasteride | Dutasteride | 68 | 19 |
| Nitroglycerin | Nitroglycerin | 66 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 64 | 57 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 64 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 22 |
| Ozempic | Semaglutide | 59 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 58 | 15 |
| Jardiance | Empagliflozin | 58 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 14 |
| Prednisone | Prednisone | 54 | 44 |
| Aripiprazole | Aripiprazole | 53 | 11 |
| Estradiol | Estradiol | 53 | 17 |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 52 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 11 |
| Ranolazine Er | Ranolazine | 51 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 51 | 18 |
| Amoxicillin | Amoxicillin | 50 | 41 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 39 |
| Gemfibrozil | Gemfibrozil | 49 | 12 |
| Azelastine Hcl | Azelastine Hcl | 48 | 22 |
| Celecoxib | Celecoxib | 47 | suppressed |
| Sucralfate | Sucralfate | 45 | 18 |
| Levofloxacin | Levofloxacin | 43 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 12 |
| Finasteride | Finasteride | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 13 |
| Rybelsus | Semaglutide | 38 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 26 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 35 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Glipizide | Glipizide | 34 | 11 |
| Meclizine Hcl | Meclizine Hcl | 34 | suppressed |
| Colchicine | Colchicine | 33 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Metronidazole | Metronidazole | 32 | 26 |
| Nortriptyline Hcl | Nortriptyline Hcl | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | 14 |
| Acyclovir | Acyclovir | 24 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 24 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 21 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Enbrel Mini | Etanercept | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 14 | 13 |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $715.15 · 47 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, EVENITY, MOUNJARO, OTEZLA, Ohtuvayre, PROLIA, REPATHA, VRAYLAR, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error